Saturday 17 October 2026 Export SUPN’s income statement to Excel — free account

Supernus Pharmaceuticals, Inc.

SUPN Healthcare Drug Manufacturers Specialty & Generic

Supernus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.0 million, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 32.4%, EPS fell 352.5% and free cash flow fell 109.3%, each against the same quarter a year earlier.

37.88 1.69 −4.27%

Follow SUPN

Alert me

Market cap: $2.3B
P/E: 0.0×
Fwd P/E: 103×
Dividend yield: —
F-score: 5/9
Altman Z: 5.41
Beneish M: −2.54
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.88

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	2	—	1	5	—	—	—	—	—	—	—

Insider Ownership 6.10%

Capital & Financial Ratios $m

Market Cap 2,300.00

Revenue 830.44

Net Income (109.89)

Free Cash Flow 18.33

Net Debt (372.07)

Current Ratio 2.08

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 103.00

P/S ratio 2.65

P/B ratio 2.13

Past 5Y EPS Growth —

This Y EPS Growth (21.64%)

Next Y EPS Growth 69.82%

Next Y revenue growth 23.21%

Next 5Y EPS Growth 18.63%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 18.36%

10-year low 10-year high

P/B against its own 10 years 44.31%

10-year low 10-year high

EV/Sales against its own 10 years 19.76%

10-year low 10-year high

EV/FCF against its own 10 years 97.20%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	255	454	309	372
Receivables	144	142	188	212
Inventory	77	54	82	84
Other	—	—	—	—
	493	686	644	723

	2023	2024	2025	Q'26
Payables	80	76	108	108
ST’ Debt	—	—	—	—
Other	56	47	69	40
	290	292	338	347

Compound Annual Growth %

	10y	5y	3y
Sales	17.17%	6.68%	2.52%
Cash Flow	3.21%	(19.31%)	(26.01%)
Earnings	0.00%	0.00%	0.00%
Book Value	28.28%	7.35%	6.21%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	208	219	—	—	—
’25	150	165	192	212	719
’24	144	168	176	174	662
’23	154	136	154	164	608
’22	153	170	177	167	667
’21	131	141	148	159	580
’20	95	127	155	144	520

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	67	(5)	—	—	—
’25	31	59	(62)	20	47
’24	38	36	54	44	172
’23	49	(19)	36	45	111
’22	4	71	14	28	117
’21	36	46	(4)	49	127
’20	9	92	6	32	138

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	67	(5)	—	—	—
’25	30	58	(62)	19	46
’24	38	36	53	44	171
’23	49	(19)	36	45	111
’22	3	72	14	28	116
’21	34	46	(4)	49	125
’20	6	91	5	32	135

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.04)	(1.01)	—	—	—
’25	(0.21)	0.40	(0.80)	(0.07)	(0.68)
’24	0.00	0.36	0.69	0.27	1.32
’23	0.29	(0.02)	(0.29)	0.02	0.02
’22	0.43	0.14	0.03	0.43	1.04
’21	0.11	0.43	0.40	0.04	0.98
’20	0.40	0.65	0.74	0.57	2.36

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	9.51	23.10	30.05	19.35	13.12	23.15	24.95	21.99	25.53	29.16	Analyst estimates 2026–2028 Powerpack
	High	27.10	50.05	61.25	43.05	27.55	34.50	38.40	42.09	39.37	57.65
People
People	Employees	363	422	448	464	563	575	612	652	674	778
	Revenue/emp, $m	0.59	0.72	0.91	0.85	0.92	1.01	1.09	0.93	0.98	0.92
Income, $m
Income, $m	Revenue	215	302	409	393	520	580	667	608	662	719
	Gross margin, %	94.43	94.97	96.24	95.76	89.92	87.05	86.93	86.21	88.23	89.63
	EBT	50	101	140	147	169	73	61	3	98	(49)
	EBT margin, %	23.43	33.29	34.28	37.55	32.41	12.62	9.10	0.46	14.79	(6.82)
	Net income	91	57	111	113	127	53	61	1	74	(39)
	Depreciation	3	8	17	18	32	51	91	85	82	90
Per share, $
Per share, $	Revenue	4.35	5.95	7.86	7.49	9.89	10.92	12.43	11.14	12.01	12.74
	Earnings	1.84	1.13	2.13	2.16	2.41	1.01	1.13	0.02	1.34	(0.68)
	Cash flow	1.35	2.26	2.48	2.73	2.63	2.39	2.18	2.04	3.12	0.84
	Capex	(0.41)	(0.04)	(0.02)	(0.03)	(0.07)	(0.04)	(0.01)	(0.01)	(0.01)	(0.02)
	Free cash flow	0.94	2.22	2.46	2.70	2.56	2.36	2.17	2.03	3.11	0.81
	Book value	3.88	5.27	8.71	11.36	14.16	15.36	16.51	16.90	18.80	18.81
	Shares, m	49	51	52	52	53	53	54	55	55	56
Valuation, ×
Valuation, ×	P/E	14.10	35.80	15.52	11.03	10.44	28.59	33.16	1,118.15	26.94	0.00
	P/S	5.97	6.79	4.22	3.17	2.54	2.67	3.01	2.49	3.01	3.90
	P/B	6.70	7.68	3.81	2.09	1.78	1.90	2.27	1.64	1.92	2.64
	EV/Sales	5.57	6.33	4.16	3.18	2.44	2.75	3.54	2.86	3.05	4.14
	EV/FCF	25.82	19.97	13.44	8.90	9.55	12.91	20.54	15.94	11.89	67.01
Cash, $m
Cash, $m	Operating cash flow	67	115	129	143	138	127	117	111	172	47
	Capex	(20)	(2)	(1)	(1)	(4)	(2)	0	(1)	(1)	(1)
	Free cash flow	46	113	128	142	135	125	116	111	171	46
Balance, $m
Balance, $m	Working capital	71	105	332	312	385	286	46	203	394	306
	Total debt	4	22	329	345	362	379	36	—	—	—
	Net debt	(86)	(118)	(27)	(2)	(61)	40	(461)	(255)	(454)	(309)
	Shareholders’ equity	192	267	453	595	745	816	886	922	1,036	1,062
Returns, %
Returns, %	ROA	36.62	15.61	15.83	10.58	9.53	3.35	3.79	0.09	5.58	(2.73)
	ROIC	32.03	41.63	21.17	15.64	15.87	6.29	6.79	(0.49)	8.77	(5.17)
	ROE	65.21	24.95	30.81	21.57	18.94	6.85	7.55	0.15	7.55	(3.68)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LQDA Liquidia Corporation	$3.1B	21.9×	18.5×	+1,842.73% (above 0%: growing)	n/m	+270.23% (above 0%: growing)	93.27%	49.81%	Compare
HCM HUTCHMED (China) Limited Sponsored ADR	$2.4B	— (loss-making)	—	+510.07% (above 0%: growing)	+419.25% (above 0%: growing)	+113.21% (above 0%: growing)	60.90%	0.00%	Compare
PBH Prestige Consumer Healthcare Inc.	$2.3B	13.9×	10.3×	+6.48% (above 0%: growing)	−36.46% (below 0%: shrinking)	−14.19% (below 0%: shrinking)	51.25%	19.77%	Compare
SUPN Supernus Pharmaceuticals, Inc.	$2.3B	— (loss-making)	103×	+32.40% (above 0%: growing)	n/m	−109.26% (below 0%: shrinking)	84.63%	(26.46%)
PRGO Perrigo Company plc	$2.3B	— (loss-making)	— (loss-making)	−3.17% (below 0%: shrinking)	n/m	+18.37% (above 0%: growing)	30.69%	2.31%	Compare
ALVO Alvotech	$2.1B	— (loss-making)	8.9×	+2,310.95% (above 0%: growing)	−99.51% (below 0%: shrinking)	−496.58% (below 0%: shrinking)	56.47%	9.14%	Compare
BCRX BioCryst Pharmaceuticals, Inc.	$2.1B	— (loss-making)	— (loss-making)	+33.61% (above 0%: growing)	+1,450.00% (above 0%: growing)	+153.22% (above 0%: growing)	98.24%	45.12%	Compare
XERS Xeris Biopharma Holdings, Inc.	$1.8B	— (loss-making)	54.5×	+28.74% (above 0%: growing)	n/m	+8,403.09% (above 0%: growing)	86.41%	5.62%	Compare
ANIP ANI Pharmaceuticals, Inc.	$1.7B	14.9×	14.5×	+25.87% (above 0%: growing)	+194.59% (above 0%: growing)	−22.19% (below 0%: shrinking)	62.35%	15.21%	Compare
Median of peers	$2.2B	14.9×	14.5×	+31.17%	+194.59%	+65.79%	61.63%	12.18%

All 86 Drug Manufacturers Specialty & Generic stocks →

Supernus Pharmaceuticals, Inc. (SUPN) key facts

Strength: Supernus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.0 million, up 8.63% from fiscal 2024.
Supernus Pharmaceuticals, Inc. (SUPN) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SUPN traded at $37.88, a market capitalization of $2.3 billion.
Return on equity was −3.68% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 5.41 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.